NOW ENROLLING! Breakfast Egg Research Study for Patients with Pre-Diabetes

Great Lakes Clinical Trials is looking for male and female volunteers for a research study involving the daily consumption of eggs (12 per week) at breakfast compared to non-egg breakfast foods. 


What is the objective of the study?
The purpose of this study is to evaluate the effects of eating eggs on metabolic health in people with increased risk of developing type 2 diabetes. 

What is my time commitment to the study?
You will be asked to visit our clinic on 7 occasions over approximately 3-4 months.  The study visits will last between 30 and 180 minutes.

Is there a study stipend?
There is no cost for participation in this study.  All study breakfast foods, tests and procedures are free of charge and we do not bill insurance.  For your participation, you will receive up to $575. 

You may be able to participate if you are:

1.     between 18-74 years old

2.     currently diagnosed as having pre-diabetes or if you are at risk for developing type 2 diabetes, as indicated by having at least 3 of the following 5 conditions:

  • overweight
  • elevated triglycerides
  • low HDL-C (high-density lipoprotein-cholesterol)
  • high blood pressure (or are on a blood pressure lowering medication)
  • elevated glucose

3.     willing to consume study-related breakfast foods 6 days per week during two 4-week test periods

Note that other entry criteria will apply and can be discussed with our study staff.  Lab values, blood pressure and weight measurements will be verified at your first clinic visit.

If you are interested in joining this trial, please call our center directly at (773) 275-3500 to speak with one of our staff today or visit

Steve Satek to Provide Opening Address at 2017 AWARE for ALL - Chicago

AWARE Chicago Title.jpg

Given the vital importance of clinical research in advancing understanding of the causes and cure for Alzheimer's Disease, mental health disorders, pain disorders and general health, Great Lakes Clinical Trials is excited to have a presence at AWARE for All: Chicago - Clinical Research Education Day.

Steve Satek, President of Great Lakes Clinical Trials

Steve Satek, President of Great Lakes Clinical Trials

Steve Satek, President of Great Lakes Clinical Trials, is proud to provide the Opening Address at this importnat conference. "After participating in past AWARE for All events as a research panelist, I am humbled to have the opportunity to address this program from a more global perspective," commented Mr. Satek.  "The goal of AWARE for All and its organizer CISCRP, falls very much in line with that of Great Lakes Clinical Trials.  We all understand the important role volunteers play in clinical research and this program supports our mission of educating and informing the public about clinical research participation." 

Clinical trials have long been a source of groundbreaking treatment developments, assistance for patients and a small source of additional income for many. AWARE for All is an educational session outlining the process, benefits and options for participation in a variety of clinical trials. The event has free health screenings, as well as information booths from local healthcare professionals and community organizations. Connect with local doctors and patients to learn how you can engage with clinical trials locally. The event begins at 5:00PM, with discussions starting at 6:00PM. There will be free dinner served, as well as giveaways. This event is free to attend however pre-event registration is encouraged.

Presented by: Center for Information and Study on Clinical Research (CISCRP)

Tickets: Free, registration encouraged.
Location: The University of Illinois Chicago Forum, 725 W Roosevelt Rd, Chicago, IL 60608

Date & Time: Thursday, October 26 from 5:00PM – 8:00PM

AWARE for All: Chicago will take place on Thursday, October 26 from 5:00PM – 8:00PM at the The University of Illinois Chicago Forum. For more information:


Call: 877-633-4376


Living with Diabetic Nerve Pain?

Aptinyx DPN (Social Media).jpg

If you have Type 2 Diabetes and are experiencing nerve pain in your feet and/or legs, you may be able to participate in a clinical trial.

An investigational drug is being studied for patients who have diabetic nerve pain (also called painful diabetic peripheral neuropathy or pain associated with diabetic peripheral neuropathy). The purpose of this study is to evaluate if the investigational drug works and determine its safety.

You may be able to participate if you:

  • Have pain associated with diabetic peripheral neuropathy in your feet and/or legs
  • Are 18-70 years of age
  • Have type 2 diabetes

The study team will also review other criteria with you to determine your full eligibility.  You will receive all study-related care and study-related drug at no cost.

This trial will involve 5 visits to our clinic over 6 to 9 weeks consisting of these steps:

  • Screening Period (1 clinic visit):  1 to 4 weeks
  • Maintenance Period (3 clinic visits):  4 weeks during which you will need to swallow 2 capsules once daily
  • Follow-up Period (1 clinic visit):  1 week after the last dose for assessment of side effects and lab tests.

If you are interested in joining this trial, please call our center directly at (773) 275-3500 to speak with one of our staff today or visit

Great Lakes Clinical Trials Participated in the Arlington Heights Senior Services Expo

Great Lakes Clinical Trials' President, Steve Satek with his mother, Pat Satek

Great Lakes Clinical Trials' President, Steve Satek with his mother, Pat Satek

Great Lakes Clinical Trials was proud to meet hundreds of seniors at the 2017 Senior Service Expo located at the state-of-the-art Arlington Heights Senior Center.  GLCT President, Steve Satek, discussed the various memory research studies ongoing at Great Lakes with a special emphasis on the studies that have started at their new location within the Lutheran Home (800 West Oakton in Arlington Heights).      

"I couldn't be happier to discuss the exciting research we are conducting at our Arlington Heights facility," commented Steve. "We partnered with the Lutheran Home to provide direct access to cutting edge research studies for both the residents of the Lutheran Home and Luther Village, as well as for all residents of the surrounding Northwest Suburban communities."

Great Lakes Clinical Trials' research programs in Arlington Heights are for seniors who are generally healthy and are not experiencing significant memory loss.  "We are studying new treatments to help prevent future memory loss," added Steve.  "Now is the time for today's seniors to participate in research and be part of the solution to ending Alzheimer's disease - before the memories are lost."

All research at Great Lakes Clinical Trials is provided free-of-charge, and insurance is not required. Research is conducted by board-certified clinicians.  For more information on the research programs and to learn how to participate, call (773) 275-3500 or click here for more information. 

Great Lakes Clinical Trials Contributes to Successful Rheumatoid Arthritis Study

Great Lakes Clinical Trials, under the direction of our board-certified rheumatologist, Dr. Manish Jain, has contributed to the successful results of our phase 3 Rheumatoid Arthritis clinical trial program.  

"I am proud of our team's work on this program," commented Steve Satek, President of Great Lakes Clinical Trials. "The true heroes of this program are our patients who participated in this program in spite of the uncertainty of risk or benefit.  Without these individuals who volunteered their time and committed to the program, there would be no advancement in medicines, no cures and no promise of a better tomorrow." 

Highlights of the press release related to the program is provided below.  Please click here to download a PDF of the full press release.



AbbVie’s Upadacitinib (ABT-494) Meets All Primary and Ranked Secondary Endpoints in Second Phase 3 Study in Rheumatoid Arthritis

SELECT-BEYOND, the second study in the robust SELECT program, demonstrated positive results with both doses (15 mg and 30 mg once-daily) meeting the primary endpoints in a difficult-to-treat patient population, over half of whom had previously been treated with two or more biologics

  • Both doses achieved low disease activity in over 40 percent of patients at week 12 and over 50 percent of patients at week 24
  • The safety profile of upadacitinib was consistent with previously reported studies, with no new safety signals detected
  • Upadacitinib, an oral agent engineered by AbbVie to selectively inhibit JAK1, is being studied as a once-daily therapy in rheumatoid arthritis in the SELECT program and across multiple immune-mediated diseases

NORTH CHICAGO, Ill., Sept. 11, 2017 – AbbVie (NYSE: ABBV), a global research and development based biopharmaceutical company, today announced positive top-line results from the Phase 3 SELECT-BEYOND clinical trial evaluating upadacitinib (ABT-494), an investigational oral JAK1-selective inhibitor, in patients with moderate to severe rheumatoid arthritis (RA) who did not adequately respond or were intolerant to treatment with biologic DMARDs (bDMARDs).  Results showed that after 12 weeks of treatment, both once-daily doses of upadacitinib (15 mg and 30 mg) met the study’s primary endpoints of ACR20 and low disease activity (LDA). All ranked secondary endpoints were also achieved with both doses. Upadacitinib is not approved by regulatory authorities and safety and efficacy have not been established. 

“We are very pleased with the positive results for upadacitinib in the SELECT-BEYOND trial. Particularly exciting is the proportion of patients who achieved clinical remission by week 12 and 24, despite having inadequate responses with previous biologic therapies,” said Michael Severino, M.D., executive vice president, research and development and chief scientific officer, AbbVie. “Together with previously reported results from SELECT-NEXT, these data further support the potential for upadacitinib to be a meaningful treatment option for rheumatoid arthritis patients. We continue to build upon our leadership in immunology as we advance the development program for upadacitinib across a broad range of immune-mediated diseases.” 

About the SELECT Study Program

The robust SELECT Phase 3 RA program evaluates more than 4,000 patients with moderate to severe rheumatoid arthritis in six studies. The studies include assessments of efficacy, safety and tolerability across multiple rheumatoid arthritis patient populations. Key measures of efficacy evaluated include ACR responses, disease activity and inhibition of radiographic progression. More information on this trial can be found at (NCT02706847, NCT03086343, NCT02629159, NCT02706873, NCT02706951, NCT02675426). 

About Upadacitinib

Discovered and developed by AbbVie, upadacitinib is an investigational oral agent engineered to selectively inhibit JAK1, which plays an important role in the pathophysiology of rheumatoid arthritis and other immune-mediated inflammatory disorders. Phase 3 trials of upadacitinib in psoriatic arthritis are ongoing and it is also being investigated to treat Crohn’s disease, ulcerative colitis, ankylosing spondylitis and atopic dermatitis.

Upadacitinib is an investigational oral agent and is not approved by regulatory authorities. Safety and efficacy have not been established. 

About AbbVie

AbbVie is a global, research-driven biopharmaceutical company committed to developing innovative advanced therapies for some of the world’s most complex and critical conditions. The company’s mission is to use its expertise, dedicated people and unique approach to innovation to markedly improve treatments across four primary therapeutic areas: immunology, oncology, virology and neuroscience. In more than 75 countries, AbbVie employees are working every day to advance health solutions for people around the world. For more information about AbbVie, please visit us at Follow @abbvie on Twitter, Facebook or LinkedIn

Forward-Looking Statements

Some statements in this news release may be forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995. The words "believe," "expect," "anticipate," "project" and similar expressions, among others, generally identify forward-looking statements. AbbVie cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those indicated in the forward-looking statements. Such risks and uncertainties include, but are not limited to, challenges to intellectual property, competition from other products, difficulties inherent in the research and development process, adverse litigation or government action, and changes to laws and regulations applicable to our industry. 

Additional information about the economic, competitive, governmental, technological and other factors that may affect AbbVie's operations is set forth in Item 1A, "Risk Factors," in AbbVie's 2016 Annual Report on Form 10-K, which has been filed with the Securities and Exchange Commission. AbbVie undertakes no obligation to release publicly any revisions to forward-looking statements as a result of subsequent events or developments, except as required by law. 

References related to the above information can be found in the full press release by clicking here

Great Lakes Clinical Trials Memory Experts Invited to Present at Alzheimer's Association Research Symposium

Great Lakes Clinical Trials is honored to have two of their memory research experts, invited to speak at the 2017 Alzheimer's Association Research Symposium, hosted by the Illinois Chapter.  Dr. Linda Rice, Board-Certified Clinical Neuropsychologist will be joined by Great Lakes Clinical Trials President, Steve Satek, to present at the educational sessions on the topic of "The Genetics of Alzheimer’s Disease. 

Steve Satek

Steve Satek

Linda Rice, PhD

Linda Rice, PhD

"Many people with Alzheimer’s Disease are concerned that they have inherited the condition and may in turn pass it on," commented Mr. Satek.  "Our presentation and discussion outlines the present state of knowledge about the genetics of Alzheimer’s Disease. Genetic risk factors will be described and explained."   Attendees will also learn what researchers know about genetics, age, chromosomes and family history and how these factors are incorporated into the design of Alzheimer’s Disease clinical trials, including the new National GeneMatch research registry.

The theme of this year's symposium is "Educate. Ignite. Integrate."  National, regional and local dementia researchers and experts will present the latest and emerging dementia-related research topics including innovative care practices, technology based care and treatment options, theories and discoveries with a special focus on translating research into care.

This year’s Symposium is being held at the Swissôtel Chicago, with stunning views of Lake Michigan and the Chicago Skyline, the Swissôtel offers an exclusive destination setting for our full-day Symposium and expo.  The street address of the venue is 323 E Upper Wacker Dr, Chicago, IL 60601.

November 2, 2017 | 7:30 a.m. - 3:30 p.m.

Physicians, researchers, health care professionals, professional caregivers, students and members of our community looking to enhance skill sets and gain insights on Alzheimer’s and dementia-related topics. CME and CEUs offered. 

To register for this event, click HERE to be taken to the Alzheimer's Association website.

Great Lakes Clinical Trials is an independent, phase I-IV clinical trials center that specializes in the study of new medications for the prevention, treatment and cure of memory disorders such as Alzheimer's Disease.  With two Chicago area locations in the Andersonville neighborhood of Chicago and in Arlington Heights, the Great Lakes team have managed more than 450 clinical trials over the past 25 years and are committed to providing quality services for both study volunteers, their caregivers & the research industry. All medical services at  Great Lakes Clinical Trials are provided free-of-charge (no insurance required).  Health information is kept confidential, unless collaboration with your personal physician is requested.  A stipend will provided for your participation - amounts vary based on each study.  Free transportation is also provided for some trials.  For more information, call (773) 275-3500.




Steve Satek to Speak at the 2017 Global Site Solutions Summit

Steve Satek, President, GLCT

Steve Satek, President, GLCT

Steve Satek, President of Great Lakes Clinical Trials (GLCT) will be speaking at the 2017 Global Site Solutions Summit.  Mr. Satek will be joined on a panel session by Beth Harper, President of Clinical Performance Partners, Inc. and Brittany Parker, Senior Manager, Marketing and Communications at Total Clinical Trial Management to speak on the topic of  on the topic of "Improve Your Bottom Line – Hidden Strategies to Achieve Your Potential." 

These experienced industry leaders, will share their knowledge on the topics of:

  • Rescue site: Position yourself now for success, without draining your resources.
  • Generic product clinical studies: Gain real potential that will surprise you.     
  • Go beyond the BIG 10: Understand the value of a great sponsor pipeline, and connect with sponsors outside of the top 10. 

The 2017 Global Site Solution Summit will be held at the Boca Raton Resort and Club, a Waldorf Astoria Resort in Boca Raton Florida from October 6-8, 2017. 

For the last 12 years, the Global Site Solutions Summit has been committed to being “the site’s meeting.” The Summit provides a unique hub where sites, sponsors, CRO executives and regulators come together and share best practices, build their businesses, and develop new partnerships through debates, ideation sessions, workshops and focus groups 


Nutritional Research Study

Great Lakes Clinical Trials is looking for male and female volunteers between the ages of 18 and 79 for an investigational research study involving the daily consumption of 4 servings of a variety of muffins and rolls containing either corn oil or coconut oil over two 4-week periods.

What is the Purpose of this Study?

The main objective of this trial is to study the effects of corn oil and coconut oil on your cholesterol measurements (lipid profile). Certain components of your lipid profile are the most commonly used markers used to determine a person’s risk of having cardiovascular disease. Researchers will also study the effects of the corn and coconut oils on your blood insulin levels and markers of inflammation.

If you take part in this study, you have an equal chance (like flipping a coin) of getting one of the following during the first treatment period:

  • Study Foods made with Corn Oil
  • Study Foods made with Coconut Oil

What is my time commitment to the study?

You will be asked to visit our clinic on 7 occasions over approximately 3 months. The study visits will last between 30 and 120 minutes.

Is there a Study Stipend?

There is no cost for participation in this study. All tests and procedures are free of charge and we do not bill insurance. For your participation you will receive $10 for the initial screening visit, $15 to complete the screening visit, $100 for visits 2 and 4, $50 for visits 3, 5, and 6, and $150 for visit 7 for a total of $525 for completing the trial.

You may be able to participate if you:

  • are between 18-79 years old
  • have elevated cholesterol levels
  • are willing to consume study-related foods (muffins and rolls) daily, during two 4-week test periods
  • are able to visit our clinic 7 times over approximately 2 months

Note that other entry criteria will apply and can be discussed with our study staff.

If you are interested in joining this trial, visit our website at or call our site directly at (773) 275-3500 to speak with one of our staff members today.

Great Lakes Clinical Trials' Generation Study Highlighted in Wall Street Journal

The following article on the Generations study and Genematch program was published in The Wall Street Journal on April 22, 2017.


The hope is that early treatment to prevent Alzheimer’s from taking hold will prove more successful than efforts to halt the disease’s progress.

By Denise Roland

April 22, 2017


Novartis AG  thinks its best bet for testing two new Alzheimer’s drugs is on people who don’t actually have Alzheimer’s.

The Swiss drug giant is looking for people whose genes put them at high risk of developing Alzheimer’s, but who haven’t yet fallen victim to the mind-robbing disease. It hopes such early treatment proves more successful than past efforts to tackle the disease once it has taken hold.

The history of Alzheimer’s research is marked by disappointment. In November, a high-profile Eli Lilly LLY 1.87% & Co. drug called solanezumab was the latest to fail a late-stage clinical trial. That drug aimed to clear clumps of a protein called beta amyloid in the brain, which are closely linked with Alzheimer’s. So far, no company has produced a drug that can delay the progression of Alzheimer’s.

One of the new Novartis drugs, known as CAD106, is designed to boost the immune system’s ability to clear beta amyloid from the blood. The other, which Novartis is developing with Amgen Inc. and is called CNP520, aims to stop its formation in the first place.

“If an anti-amyloid strategy is going to work, the best way to do so is with prevention,” said Steven Arnold, a neurologist at Massachusetts General Hospital in Boston.

Recruiting patients to receive treatment for a disease they don’t have—and may never develop—is riven with logistical and ethical challenges.

The company is looking for people with two copies of a gene called APOE4 to participate in its study. Having two copies of the gene doesn’t inevitably lead to Alzheimer’s, but the roughly 2% of people who fit this profile are around three times as likely to develop dementia as the general population, according to a recent analysis in the scientific journal PLOS Medicine.

The Banner Alzheimer’s Institute, a Phoenix nonprofit, is helping Novartis find eligible participants with a campaign launched at the end of 2015 to test people for the APOE4 gene. The institute places television and newspaper ads, does mass mailings and runs events in clinics to publicize the program, called Genematch.

So far, around 35,000 people have signed up, agreeing to send swabs of their cheek cells for testing. “We seem to have tapped into a very motivated group of people,” said Pierre Tariot, director of Banner. “Not surprisingly, a lot of them have a family history of Alzheimer’s.”

Amyloid plaque deposition in a person with Alzheimer's dementia, left; a person who is cognitively unimpaired but at high risk for developing Alzheimer's symptoms, center, and an unimpaired person at low risk, right.

Margaret, a 71-year-old from Virginia, discovered two weeks ago that she has two copies of the APOE4 gene. She signed up for the Genematch program earlier this year after hearing about it through the hospital that is caring for her older sister, who has Alzheimer’s.

“It is shocking,” said Margaret, who declined to give her last name because she hasn’t yet told her family. But “if this works and can prevent or slow it down, then obviously I’d like to participate. That part of it is a no-brainer.”

Only a fraction those who sign up will be eligible for the trial. As well as having two copies of the APOE4 gene, participants in the Novartis study must be healthy, between the ages of 60 and 75, and have no outward signs of Alzheimer’s, such as cognitive decline. Fewer than 10% of the roughly 1,300 participants needed for the trial have been recruited so far, Dr. Tariot said.

The Genematch staff doesn’t know any individual participant’s genetic results. Instead, a computer program provides a list of names—only some of whom are genetic matches—for them to call. On that call, Genematch will tell the person they might be eligible for a trial and tell them about nearby participating hospitals.

Participants are informed of their genetic profile—usually by a genetic counselor—only after a lengthy assessment by staff at the clinical-trial site to determine that they are eligible for, and willing to enroll in, the study.

“The critical thing is that this is done in a highly ethical way,” said Vas Narasimhan, global head of drug development at Novartis. “If a patient is not selected for the study, we are not intervening to help them so there is no reason to provide them with this information.”

The Novartis study is among a small group of trials that might still vindicate the beta amyloid-targeting approach to Alzheimer’s drugs. Shown, a building on the Swiss pharmaceutical giant’s campus in Basel in 2015.

Later this year, Novartis plans to start a further trial that will be open to people who have just one copy of the APOE4 gene, Dr. Narasimhan said. Around a quarter of the population is thought to fit this profile, and they are about 1½ times as likely to develop mild cognitive impairment or dementia as the general population.

After the string of high-profile failures in amyloid-busting drugs, experts are divided over whether they are the right approach to tackling Alzheimer’s. “The field is very pessimistic right now,” said Murali Doraiswamy, director of the neurocognitive disorders program at Duke University Health System in Durham, N.C.

But the Novartis study was among a small group of trials that could still vindicate this approach, Dr. Doraiswamy said. “We’ve learned a lot from previous [failed] trials,” he said, adding that the “elegant” design of the Novartis study—in focusing on a narrow band of people known to have heightened risk of Alzheimer’s—makes it a “near-perfect model to test the amyloid thesis.”

Swedish Covenant Hospital Hosts A Free Family-Oriented Community Event

Please join Great Lakes Clinical Trials in supporting Swedish Covenant Hospital's upcoming Summer Social.  It's fun for everyone! Admission is FREE so bring the whole family to enjoy this rain or shine event:

  • Free bike helmets (for the first 1,000 attendees) provided by Swedish Covenant Hospital
  • Live entertainment and DJ
  • Bouncy houses
  • Face painter and balloon artist
  • Helmet decorating and other kids activities
  • Summer safety giveaways and bike safety tips
  • Food trucks
  • Raffle prizes and more!

The event will be held in the parking lot of Galter LifeCenter at 5115 N. Francisco. FREE parking in Swedish Covenant Hospital’s garage (entrance at California & Winona). We will have a big bike rack and also a DIVVY station onsite.

More info: